Tumor-infiltrating lymphocyte (TIL) therapy is a promising new approach to cancer therapy that harnesses the body’s own immune system to treat diseases like melanoma, a type of skin disease, an expert said.
2024
Yeppoon family shares devastating melanoma journey in hope it saves lives
Lyell Duffy thought he had pulled a muscle at work when he began experiencing back pain.
Low Neutrophil-Lymphocyte Ratio Linked to Better Survival in Some Melanoma Cases
Baseline neutrophil-lymphocyte ratio (NLR) is a significant predictor of disease progression and overall survival (OS) in patients with metastatic melanoma undergoing programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) blockade therapy, according to study results published in Melanoma Research.
Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors
Victor Moreno, MD, PhD, medical oncologist, director, Clinical Research, START Madrid-Fundación Jimenez Diaz (FJD), discusses insights into the pharmacodynamic data for CLN-619, a novel humanized IgG1 antibody designed to bind to MICA and MICB, in patients with advanced solid tumors. Findings were presented by Moreno and colleagues during the 2024 SITC Annual Meeting.